Skip to Content

Uplizna Approval History

FDA Approved: Yes (First approved June 11, 2020)
Brand name: Uplizna
Generic name: inebilizumab-cdon
Dosage form: Injection
Company: Viela Bio
Treatment for: Neuromyelitis Optica Spectrum Disorder (NMOSD)

Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Development History and FDA Approval Process for Uplizna

DateArticle
Jun 13, 2020Approval FDA Approves Uplizna (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.